Operative Management of Cholangiocarcinoma

Abstract

Cholangiocarcinomas (CCAs) are rare malignancies that originate from the epithelial cells of the bile ducts. It is the second most-common primary liver cancer after hepatocellular carcinoma. Recent epidemiologic studies have shown that the overall incidence and mortality rates of CCAs are increasing. Diagnosis is often challenging due to the difficulty in getting tissue/cytology for confirmation, and it comprises a combination of cross-imaging, tumor markers, histology, and cholangiography. Surgery involving major resections of liver, bile duct, pancreas, and at times adjacent vessels is the only chance for cure. Evaluation should be focused on the assessment of tumor resectability, hepatic reserve, and patient physiological fitness for major surgery. In patients not fit for major surgery, biliary drainage for jaundice is an appropriate intervention and if there is histologic confirmation of a CCA, palliative therapies focused on local and systemic disease control should be considered. The endeavor to expand the indications for liver transplantation reflects the efforts to provide an effective form of therapy for a previously untreatable disease. A multidisciplinary specialized approach should be the platform for providing the best comprehensive care for these patients.

Keywords

cholangiocarcinoma - liver resection - liver transplantation - bile duct cancer

• References

• 1 Vauthey JN, Blumgart LH. Recent advances in the management of cholangiocarcinomas. Semin Liver Dis 1994; 14 (2) 109-114
• 2 Dasanu CA, Majumder S, Trikudanathan G. Emerging pharmacotherapeutic strategies for cholangiocarcinoma. Expert Opin Pharmacother 2011; 12 (12) 1865-1874
• 3 Nakeeb A, Pitt HA, Sohn TA , et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996; 224 (4) 463-473 , discussion 473–475
• 4 Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005; 366 (9493) 1303-1314
• 5 Welzel TM, Graubard BI, El-Serag HB , et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol 2007; 5 (10) 1221-1228
• 6 Endo I, Gonen M, Yopp AC , et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 2008; 248 (1) 84-96
• 7 Olnes MJ, Erlich R. A review and update on cholangiocarcinoma. Oncology 2004; 66 (3) 167-179
• 8 Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford) 2008; 10 (2) 77-82
• 9 Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004; 24 (2) 115-125
• 10 Khan SA, Davidson BR, Goldin RD , et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut 2012; 61 (12) 1657-1669
• 11 Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 2008; 48 (1) 308-321
• 12 Sempoux C, Jibara G, Ward SC , et al. Intrahepatic cholangiocarcinoma: new insights in pathology. Semin Liver Dis 2011; 31 (1) 49-60
• 13 Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 2005; 128 (3) 620-626
• 14 Nkontchou G, Tran Van Nhieu J, Ziol M , et al. Peripheral intrahepatic cholangiocarcinoma occurring in patients without cirrhosis or chronic bile duct diseases: epidemiology and histopathology of distant nontumoral liver in 57 White patients. Eur J Gastroenterol Hepatol 2013; 25 (1) 94-98
• 15 Nagorney DM, Donohue JH, Farnell MB, Schleck CD, Ilstrup DM. Outcomes after curative resections of cholangiocarcinoma. Arch Surg 1993; 128 (8) 871-877 , discussion 877–879
• 16 Khan SA, Davidson BR, Goldin R , et al; British Society of Gastroenterology. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002; 51 (Suppl. 06) VI1-VI9
• 17 Nehls O, Gregor M, Klump B. Serum and bile markers for cholangiocarcinoma. Semin Liver Dis 2004; 24 (2) 139-154
• 18 Ghazale A, Chari ST, Zhang L , et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 2008; 134 (3) 706-715
• 19 Khan SA, Davidson BR, Goldin R , et al; British Society of Gastroenterology. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002; 51 (Suppl. 06) VI1-VI9
• 20 Patel T. Cholangiocarcinoma–controversies and challenges. Nat Rev Gastroenterol Hepatol 2011; 8 (4) 189-200
• 21 Takahashi Y, Nagino M, Nishio H, Ebata T, Igami T, Nimura Y. Percutaneous transhepatic biliary drainage catheter tract recurrence in cholangiocarcinoma. Br J Surg 2010; 97 (12) 1860-1866
• 22 Siddiqui AA, Mehendiratta V, Jackson W, Loren DE, Kowalski TE, Eloubeidi MA. Identification of cholangiocarcinoma by using the Spyglass Spyscope system for peroral cholangioscopy and biopsy collection. Clin Gastroenterol Hepatol 2012; 10 (5) 466-471 , quiz e48
• 23 Gleeson FC, Rajan E, Levy MJ , et al. EUS-guided FNA of regional lymph nodes in patients with unresectable hilar cholangiocarcinoma. Gastrointest Endosc 2008; 67 (3) 438-443
• 24 Stavropoulos S, Larghi A, Verna E, Battezzati P, Stevens P. Intraductal ultrasound for the evaluation of patients with biliary strictures and no abdominal mass on computed tomography. Endoscopy 2005; 37 (8) 715-721
• 25 Krishna NB, Saripalli S, Safdar R, Agarwal B. Intraductal US in evaluation of biliary strictures without a mass lesion on CT scan or magnetic resonance imaging: significance of focal wall thickening and extrinsic compression at the stricture site. Gastrointest Endosc 2007; 66 (1) 90-96
• 26 Petrowsky H, Wildbrett P, Husarik DB , et al. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol 2006; 45 (1) 43-50
• 27 Corvera CU, Blumgart LH, Akhurst T , et al. 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg 2008; 206 (1) 57-65
• 28 Nathan H, Aloia TA, Vauthey JN , et al. A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol 2009; 16 (1) 14-22
• 29 Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 2011; 8 (9) 512-522
• 30 Yamasaki S. Intrahepatic cholangiocarcinoma: macroscopic type and stage classification. J Hepatobiliary Pancreat Surg 2003; 10 (4) 288-291
• 31 Okabayashi T, Yamamoto J, Kosuge T , et al. A new staging system for mass-forming intrahepatic cholangiocarcinoma: analysis of preoperative and postoperative variables. Cancer 2001; 92 (9) 2374-2383
• 32 Farges O, Fuks D, Le Treut YP , et al. AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: By the AFC-IHCC-2009 Study Group. Cancer 2011; 117 (10) 2170-2177
• 33 Jarnagin WR, Fong Y, DeMatteo RP , et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001; 234 (4) 507-517 , discussion 517–519
• 34 Matsuo K, Rocha FG, Ito K , et al. The Blumgart preoperative staging system for hilar cholangiocarcinoma: analysis of resectability and outcomes in 380 patients. J Am Coll Surg 2012; 215 (3) 343-355
• 35 Yoshida T, Matsumoto T, Sasaki A , et al. Prognostic factors after pancreatoduodenectomy with extended lymphadenectomy for distal bile duct cancer. Arch Surg 2002; 137 (1) 69-73
• 36 House MG, D'Angelica MI, Jarnagin WR. Cancer of the bile ducts: extrahepatic biliary tumors. In: Jarnagin WR, , ed. Blumgart's Surgery of the Liver, Biliary Tract and Pancreas. 5th ed. Philadelphia, PA: Elsevier Saunders; 2012: 771-788
• 37 Jarnagin WR, Bowne W, Klimstra DS , et al. Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma. Ann Surg 2005; 241 (5) 703-712 ; discussion 712–704
• 38 Nuzzo G, Giuliante F, Ardito F , et al. Improvement in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patients. Arch Surg 2012; 147 (1) 26-34
• 39 Nagino M. Perihilar cholangiocarcinoma: a surgeon's viewpoint on current topics. J Gastroenterol 2012; 47 (11) 1165-1176
• 40 Zografos GN, Farfaras A, Zagouri F, Chrysikos D, Karaliotas K. Cholangiocarcinoma: principles and current trends. Hepatobiliary Pancreat Dis Int 2011; 10 (1) 10-20
• 41 Cherqui D, Benoist S, Malassagne B, Humeres R, Rodriguez V, Fagniez PL. Major liver resection for carcinoma in jaundiced patients without preoperative biliary drainage. Arch Surg 2000; 135 (3) 302-308
• 42 Laurent A, Tayar C, Cherqui D. Cholangiocarcinoma: preoperative biliary drainage (Con). HPB (Oxford) 2008; 10 (2) 126-129
• 43 Farges O, Regimbeau JM, Fuks D , et al. Multicentre European study of preoperative biliary drainage for hilar cholangiocarcinoma. Br J Surg 2013; 100 (2) 274-283
• 44 Kennedy TJ, Yopp A, Qin Y , et al. Role of preoperative biliary drainage of liver remnant prior to extended liver resection for hilar cholangiocarcinoma. HPB (Oxford) 2009; 11 (5) 445-451
• 45 Liu F, Li Y, Wei Y, Li B. Preoperative biliary drainage before resection for hilar cholangiocarcinoma: whether or not? A systematic review. Dig Dis Sci 2011; 56 (3) 663-672
• 46 Nguyen K, Sing Jr JT. Review of endoscopic techniques in the diagnosis and management of cholangiocarcinoma. World J Gastroenterol 2008; 14 (19) 2995-2999
• 47 De Palma GD, Galloro G, Siciliano S, Iovino P, Catanzano C. Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: results of a prospective, randomized, and controlled study. Gastrointest Endosc 2001; 63 (6) 547-553
• 48 Agrawal S, Belghiti J. Oncologic resection for malignant tumors of the liver. Ann Surg 2011; 253 (4) 656-665
• 49 Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation 2000; 69 (8) 1633-1637
• 50 Rosen CB, Heimbach JK, Gores GJ. Liver transplantation for cholangiocarcinoma. In, Transpl Int. England; 2010: 692-697
• 51 Koea J. Cancer of the bile ducts: intrahepatic cholangiocarcinoma. In: J W ed, Blumgart's Surgery of the Liver, Pancreas and Biliary Tract. 5th ed: Elsevier Saunders; 2012: 761-770
• 52 Friman S. Cholangiocarcinoma—current treatment options. Scand J Surg 2011; 100 (1) 30-34
• 53 Jonas S, Thelen A, Benckert C , et al. Extended liver resection for intrahepatic cholangiocarcinoma: a comparison of the prognostic accuracy of the fifth and sixth editions of the TNM classification. Ann Surg 2009; 249 (2) 303-309
• 54 Ellis MC, Cassera MA, Vetto JT, Orloff SL, Hansen PD, Billingsley KG. Surgical treatment of intrahepatic cholangiocarcinoma: outcomes and predictive factors. HPB (Oxford) 2011; 13 (1) 59-63
• 55 Sarmiento JM, Bower TC, Cherry KJ, Farnell MB, Nagorney DM. Is combined partial hepatectomy with segmental resection of inferior vena cava justified for malignancy?. Arch Surg 2003; 138 (6) 624-630 , discussion 630–631
• 56 Azoulay D, Andreani P, Maggi U , et al. Combined liver resection and reconstruction of the supra-renal vena cava: the Paul Brousse experience. Ann Surg 2006; 244 (1) 80-88
• 57 Chu KM, Fan ST. Intrahepatic cholangiocarcinoma in Hong Kong. J Hepatobiliary Pancreat Surg 1999; 6 (2) 149-153
• 58 Yamamoto M, Takasaki K, Yoshikawa T. Extended resection for intrahepatic cholangiocarcinoma in Japan. In, J Hepatobiliary Pancreat Surg. Japan 1999; 117-121
• 59 Ercolani G, Vetrone G, Grazi GL , et al. Intrahepatic cholangiocarcinoma: primary liver resection and aggressive multimodal treatment of recurrence significantly prolong survival. Ann Surg 2010; 252 (1) 107-114
• 60 Ercolani G, Grazi GL, Ravaioli M , et al. The role of lymphadenectomy for liver tumors: further considerations on the appropriateness of treatment strategy. Ann Surg 2004; 239 (2) 202-209
• 61 Isaji S, Kawarada Y, Taoka H , et al. Clinicopathological features and outcome of hepatic resection for intrahepatic cholangiocarcinoma in Japan. J Hepatobiliary Pancreat Surg 1999; 6 (2) 108-116
• 62 Jan YY, Yeh CN, Yeh TS, Hwang TL, Chen MF. Clinicopathological factors predicting long-term overall survival after hepatectomy for peripheral cholangiocarcinoma. World J Surg 2005; 29 (7) 894-898
• 63 Bismuth H, Nakache R, Diamond T. Management strategies in resection for hilar cholangiocarcinoma. Ann Surg 1992; 215 (1) 31-38
• 64 Seyama Y, Makuuchi M. Current surgical treatment for bile duct cancer. World J Gastroenterol 2007; 13 (10) 1505-1515
• 65 Sano T, Nimura Y. Extended hepatic resections for biliary tumors: an alternative approach. In: Jarnagin WR, , ed. Blumgart's Surgery of the Liver, Biliary Tract, and Pancreas. Philadelphia, PA: Elsevier; 2012: 1512-1519
• 66 Nagino M, Kamiya J, Arai T, Nishio H, Ebata T, Nimura Y. “Anatomic” right hepatic trisectionectomy (extended right hepatectomy) with caudate lobectomy for hilar cholangiocarcinoma. Ann Surg 2006; 243 (1) 28-32
• 67 Natsume S, Ebata T, Yokoyama Y , et al. Clinical significance of left trisectionectomy for perihilar cholangiocarcinoma: an appraisal and comparison with left hepatectomy. Ann Surg 2012; 255 (4) 754-762
• 68 Urahashi T, Yamamoto M, Ohtsubo T, Katsuragawa H, Katagiri S, Takasaki K. Hepatopancreatoduodenectomy could be allowed for patients with advanced intrahepatic cholangiocarcinoma. Hepatogastroenterology 2007; 54 (74) 346-349
• 69 Neuhaus P, Thelen A, Jonas S , et al. Oncological superiority of hilar en bloc resection for the treatment of hilar cholangiocarcinoma. Ann Surg Oncol 2012; 19 (5) 1602-1608
• 70 Neuhaus P, Thelen A. Radical surgery for right-sided Klatskin tumor. HPB (Oxford) 2008; 10 (3) 171-173
• 71 Neuhaus P, Jonas S, Bechstein WO , et al. Extended resections for hilar cholangiocarcinoma. Ann Surg 1999; 230 (6) 808-818 , discussion 819
• 72 Shimada H, Endo I, Sugita M , et al. Hepatic resection combined with portal vein or hepatic artery reconstruction for advanced carcinoma of the hilar bile duct and gallbladder. World J Surg 2003; 27 (10) 1137-1142
• 73 Lee SG, Song GW, Hwang S , et al. Surgical treatment of hilar cholangiocarcinoma in the new era: the Asan experience. J Hepatobiliary Pancreat Sci 2010; 17 (4) 476-489
• 74 Nagino M, Nimura Y, Nishio H , et al. Hepatectomy with simultaneous resection of the portal vein and hepatic artery for advanced perihilar cholangiocarcinoma: an audit of 50 consecutive cases. Ann Surg 2010; 252 (1) 115-123
• 75 Kondo S, Katoh H, Hirano S, Ambo Y, Tanaka E, Okushiba S. Portal vein resection and reconstruction prior to hepatic dissection during right hepatectomy and caudate lobectomy for hepatobiliary cancer. Br J Surg 2003; 90 (6) 694-697
• 76 Lang H, Sotiropoulos GC, Malagó M, Broelsch CE. Mesohepatectomy, caudate lobectomy and resection of hilar bifurcation with biliary reconstruction by 6 hepaticojejunostomies for Klatskin tumor. Hepatogastroenterology 2003; 50 (53) 1327-1329
• 77 Sakamoto Y, Kosuge T, Shimada K , et al. Prognostic factors of surgical resection in middle and distal bile duct cancer: an analysis of 55 patients concerning the significance of ductal and radial margins. Surgery 2005; 137 (4) 396-402
• 78 DeOliveira ML, Cunningham SC, Cameron JL , et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007; 245 (5) 755-762
• 79 Allen PJ, Reiner AS, Gonen M , et al. Extrahepatic cholangiocarcinoma: a comparison of patients with resected proximal and distal lesions. HPB (Oxford) 2008; 10 (5) 341-346
• 80 van der Gaag NA, Kloek JJ, de Bakker JK , et al. Survival analysis and prognostic nomogram for patients undergoing resection of extrahepatic cholangiocarcinoma. Ann Oncol 2012; 23 (10) 2642-2649
• 81 Yamamoto J, Kosuge T, Takayama T , et al. Surgical treatment of intrahepatic cholangiocarcinoma: four patients surviving more than five years. Surgery 1992; 111 (6) 617-622
• 82 Cherqui D, Tantawi B, Alon R , et al. Intrahepatic cholangiocarcinoma. Results of aggressive surgical management. Arch Surg 1995; 130 (10) 1073-1078
• 83 Yamanaka N, Okamoto E, Ando T , et al. Clinicopathologic spectrum of resected extraductal mass-forming intrahepatic cholangiocarcinoma. Cancer 1995; 76 (12) 2449-2456
• 84 Chou FF, Sheen-Chen SM, Chen CL, Chen YS, Chen MC. Prognostic factors of resectable intrahepatic cholangiocarcinoma. J Surg Oncol 1995; 59 (1) 40-44
• 85 Pichlmayr R, Lamesch P, Weimann A, Tusch G, Ringe B. Surgical treatment of cholangiocellular carcinoma. World J Surg 1995; 19 (1) 83-88
• 86 Berdah SV, Delpero JR, Garcia S, Hardwigsen J, Le Treut YP. A western surgical experience of peripheral cholangiocarcinoma. Br J Surg 1996; 83 (11) 1517-1521
• 87 Casavilla FA, Marsh JW, Iwatsuki S , et al. Hepatic resection and transplantation for peripheral cholangiocarcinoma. J Am Coll Surg 1997; 185 (5) 429-436
• 88 Madariaga JR, Iwatsuki S, Todo S, Lee RG, Irish W, Starzl TE. Liver resection for hilar and peripheral cholangiocarcinomas: a study of 62 cases. Ann Surg 1998; 227 (1) 70-79
• 89 Nozaki Y, Yamamoto M, Ikai I , et al. Reconsideration of the lymph node metastasis pattern (N factor) from intrahepatic cholangiocarcinoma using the International Union Against Cancer TNM staging system for primary liver carcinoma. Cancer 1998; 83 (9) 1923-1929
• 90 Bioulac-Sage P, Balabaud C, Zucman-Rossi J. [Interest of immunohistochemistry for the diagnosis of benign hepatocellular tumors]. Ann Pathol 2010; 30 (6) 439-447
• 91 Valverde A, Bonhomme N, Farges O , et al. Resection of intrahepatic cholangiocarcinoma: a Western experience. J Hepatobiliary Pancreat Surg 1999; 6 (2) 122-127
• 92 Isa T, Kusano T, Shimoji H , et al. Predictive factors for long-term survival in patients with intrahepatic cholangiocarcinoma. Am J Surg 2001; 181 (6) 507-511
• 93 Kawarada Y, Yamagiwa K, Das BC. Analysis of the relationships between clinicopathologic factors and survival time in intrahepatic cholangiocarcinoma. Am J Surg 2002; 183 (6) 679-685
• 94 Suzuki S, Sakaguchi T, Yokoi Y , et al. Clinicopathological prognostic factors and impact of surgical treatment of mass-forming intrahepatic cholangiocarcinoma. World J Surg 2002; 26 (6) 687-693
• 95 Ohtsuka M, Ito H, Kimura F , et al. Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival. Br J Surg 2002; 89 (12) 1525-1531
• 96 Morimoto Y, Tanaka Y, Ito T , et al. Long-term survival and prognostic factors in the surgical treatment for intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 2003; 10 (6) 432-440
• 97 Uenishi T, Yamazaki O, Yamamoto T , et al. Serosal invasion in TNM staging of mass-forming intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 2005; 12 (6) 479-483
• 98 Lang H, Sotiropoulos GC, Frühauf NR , et al. Extended hepatectomy for intrahepatic cholangiocellular carcinoma (ICC): when is it worthwhile? Single center experience with 27 resections in 50 patients over a 5-year period. Ann Surg 2005; 241 (1) 134-143
• 99 Lang H, Kaiser GM, Zöpf T , et al. [Surgical therapy of hilar cholangiocarcinoma]. Chirurg 2006; 77 (4) 325-334
• 100 Yamashita Y, Taketomi A, Morita K , et al. The impact of surgical treatment and poor prognostic factors for patients with intrahepatic cholangiocarcinoma: retrospective analysis of 60 patients. Anticancer Res 2008; 28 (4C) 2353-2359
• 101 Nakagohri T, Kinoshita T, Konishi M, Takahashi S, Gotohda N. Surgical outcome and prognostic factors in intrahepatic cholangiocarcinoma. World J Surg 2008; 32 (12) 2675-2680
• 102 Guglielmi A, Ruzzenente A, Campagnaro T , et al. Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection. World J Surg 2009; 33 (6) 1247-1254
• 103 Li SQ, Liang LJ, Hua YP , et al. Long-term outcome and prognostic factors of intrahepatic cholangiocarcinoma. Chin Med J (Engl) 2009; 122 (19) 2286-2291
• 104 Lang H, Sotiropoulos GC, Sgourakis G , et al. Operations for intrahepatic cholangiocarcinoma: single-institution experience of 158 patients. J Am Coll Surg 2009; 208 (2) 218-228
• 105 Saxena A, Chua TC, Sarkar A, Chu F, Morris DL. Clinicopathologic and treatment-related factors influencing recurrence and survival after hepatic resection of intrahepatic cholangiocarcinoma: a 19-year experience from an established Australian hepatobiliary unit. J Gastrointest Surg 2010; 14 (7) 1128-1138
• 106 Cho SY, Park SJ, Kim SH , et al. Survival analysis of intrahepatic cholangiocarcinoma after resection. Ann Surg Oncol 2010; 17 (7) 1823-1830
• 107 Murakami Y, Uemura K, Sudo T , et al. Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma. Ann Surg Oncol 2011; 18 (3) 651-658
• 108 Saiura A, Yamamoto J, Kokudo N , et al. Intrahepatic cholangiocarcinoma: analysis of 44 consecutive resected cases including 5 cases with repeat resections. Am J Surg 2011; 201 (2) 203-208
• 109 de Jong MC, Nathan H, Sotiropoulos GC , et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol 2011; 29 (23) 3140-3145
• 110 Chen LP, Li C, Wang C, Wen TF, Yan LN, Li B. Predictive factors of recurrence for patients with intrahepatic cholangiocarcinoma after hepatectomy. Hepatogastroenterology 2012; 59 (118) 1765-1768
• 111 Liu ZH, Chen Z, Ma LL, Li XH, Wang LX. Factors influencing the prognosis of patients with intrahepatic cholangiocarcinoma. Acta Gastroenterol Belg 2012; 75 (2) 215-218
• 112 Ribero D, Pinna AD, Guglielmi A , et al. Surgical approach for long-term survival of patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis of 434 patients. Arch Surg 2012; ; 147(12) 1-7
• 113 Silva MA, Tekin K, Aytekin F, Bramhall SR, Buckels JA, Mirza DF. Surgery for hilar cholangiocarcinoma; a 10 year experience of a tertiary referral centre in the UK. Eur J Surg Oncol 2005; 31 (5) 533-539
• 114 Li H, Qin Y, Cui Y , et al. Analysis of the surgical outcome and prognostic factors for hilar cholangiocarcinoma: a Chinese experience. Dig Surg 2011; 28 (3) 226-231
• 115 Saxena A, Chua TC, Chu FC, Morris DL. Improved outcomes after aggressive surgical resection of hilar cholangiocarcinoma: a critical analysis of recurrence and survival. Am J Surg 2011; 202 (3) 310-320
• 116 Regimbeau JM, Fuks D, Le Treut YP , et al; AFC-HC study group. Surgery for hilar cholangiocarcinoma: a multi-institutional update on practice and outcome by the AFC-HC study group. J Gastrointest Surg 2011; 15 (3) 480-488
• 117 Veillette G, Castillo CF. Distal biliary malignancy. Surg Clin North Am 2008; 88 (6) 1429-1447 , xi
• 118 Fong Y, Blumgart LH, Lin E, Fortner JG, Brennan MF. Outcome of treatment for distal bile duct cancer. Br J Surg 1996; 83 (12) 1712-1715
• 119 Qiao QL, Zhang TP, Guo JC , et al. Prognostic factors after pancreatoduodenectomy for distal bile duct cancer. Am Surg 2011; 77 (11) 1445-1448
• 120 Darwish Murad S, Kim WR, Harnois DM , et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 2012; 143 (1) 88-98 e83; quiz e14
• 121 Foo ML, Gunderson LL, Bender CE, Buskirk SJ. External radiation therapy and transcatheter iridium in the treatment of extrahepatic bile duct carcinoma. Int J Radiat Oncol Biol Phys 1997; 39 (4) 929-935
• 122 Rosen CB, Murad SD, Heimbach JK , et al. Neoadjuvant therapy and liver transplantation for hilar cholangiocarcinoma: is pretreatment pathological confirmation of diagnosis necessary?. J Am Coll Surg 2012; 215 (1) 31-38 ; discussion 38–40
• 123 Rosen CB, Heimbach JK, Gores GJ. Surgery for cholangiocarcinoma: the role of liver transplantation. HPB (Oxford) 2008; 10 (3) 186-189
• 124 Mazzaferro V, Bhoori S, Sposito C , et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl 2011; 17 (Suppl. 02) S44-S57
• 125 Yao FY. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant 2008; 8 (10) 1982-1989
• 126 Cauchy F, Fuks D, Belghiti J. HCC: current surgical treatment concepts. Langenbecks Arch Surg 2012; 397 (5) 681-695
• 127 Gores GJ, Gish RG, Sudan D, Rosen CB. MELD Exception Study Group. Model for end-stage liver disease (MELD) exception for cholangiocarcinoma or biliary dysplasia. Liver Transpl 2006; 12 (12) (Suppl. 03) S95-S97
• 128 Robles R, Figueras J, Turrión VS , et al. Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma. Ann Surg 2004; 239 (2) 265-271
• 129 Hong JC, Jones CM, Duffy JP , et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center. Arch Surg 2011; 146 (6) 683-689
• 130 Saxena A, Bester L, Chua TC, Chu FC, Morris DL. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol 2010; 17 (2) 484-491
• 131 Gatto M, Alvaro D. Cholangiocarcinoma: risk factors and clinical presentation. Eur Rev Med Pharmacol Sci 2010; 14 (4) 363-367
• 132 Gatto M, Bragazzi MC, Semeraro R , et al. Cholangiocarcinoma: update and future perspectives. Dig Liver Dis 2010; 42 (4) 253-260
• 133 Braconi C, Patel T. Cholangiocarcinoma: new insights into disease pathogenesis and biology. Infect Dis Clin North Am 2010; 24 (4) 871-884 , vii
• 134 Kim JY, Kim MH, Lee TY , et al. Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterol 2008; 103 (5) 1145-1151
• 135 Manfredi R, Barbaro B, Masselli G, Vecchioli A, Marano P. Magnetic resonance imaging of cholangiocarcinoma. Semin Liver Dis 2004; 24 (2) 155-164
• 136 Brugge WR. Endoscopic techniques to diagnose and manage biliary tumors. J Clin Oncol 2005; 23 (20) 4561-4565
• 137 De Vreede I, Steers JL, Burch PA , et al. Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transpl 2000; 6 (3) 309-316